டைபாய்டு ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from டைபாய்டு ப்ரோக்ர்யாம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In டைபாய்டு ப்ரோக்ர்யாம் Today - Breaking & Trending Today

Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study

Vi-DT typhoid conjugate vaccine met primary endpoints in phase III study
Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal.
The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®.
Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT. ....

South Korea , Sushant Sahastrabuddhe , Tarun Saluja , Emily Henderson , World Health Organization , Ministry Of Food , International Vaccine Institute , Typhoid Program , United Nations , Marketing Authorization , Korean Ministry , Drug Safety , World Health , International Vaccine , Jae Yong Ahn , தெற்கு கொரியா , தருண் சலுஜா , எமிலி ஹென்டர்சன் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , அமைச்சகம் ஆஃப் உணவு , சர்வதேச தடுப்பூசி நிறுவனம் , டைபாய்டு ப்ரோக்ர்யாம் , ஒன்றுபட்டது நாடுகள் , சந்தைப்படுத்தல் அங்கீகாரம் , கொரியன் அமைச்சகம் , மருந்து பாதுகாப்பு ,

IVI-SK's new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal

IVI-SK s new typhoid conjugate vaccine meets primary endpoints in phase III study in Nepal
December 17, 2020 - SEOUL, South Korea - Vi-DT typhoid conjugate vaccine, developed jointly by the International Vaccine Institute (IVI) and SK bioscience, has met the primary endpoints in a phase III study in Nepal. The primary endpoints were based on immune non-inferiority with the WHO-prequalified typhoid conjugate vaccine, Typbar-TCV®, in terms of serconversion rate, which confirms the new candidate TCV induces an immune response that is not inferior to Typbar-TCV®.
Three different production lots of vaccine were administered in the clinical trial, and the analysis also shows that these different batches were similar in immunogenicity. Lot-to-lot consistency in manufacturing is an important requirement to ensure the quality of Vi-DT. ....

Soult Ukpyolsi , South Korea , Sushant Sahastrabuddhe , Typhis Typhi , Tarun Saluja , United Nations Development Programme , Global Media Communications Specialist , World Health Organization , Typhoid Program , International Vaccine Institute , Ministry Of Food , United Nations , Marketing Authorization , Korean Ministry , Drug Safety , World Health , Jae Yong Ahn , Clininfect Dis , Global Media , Communications Specialist , தெற்கு கொரியா , தருண் சலுஜா , ஒன்றுபட்டது நாடுகள் வளர்ச்சி ப்ரோக்ராம் , உலகளாவிய மீடியா தகவல்தொடர்புகள் நிபுணர் , உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந் , டைபாய்டு ப்ரோக்ர்யாம் ,